Beatrice Sani1,2, Alessandro Cignetti2, Marta Leporati3, Sara Sommariva4, Marco Armenio1, Valerio Tenace5, Arianna Savi2, Johanna Umurungi1,2, Giovanni Fornari1,2, Simone Busso3, Alessandra Canevaro3, Igor Bisognin3, Silvia Marini1, Michele Piana4, Daniela Cilloni1,2, Valentina Gaidano2,*
Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.078245
- 16 July 2026
Abstract Objectives: Venetoclax (VEN) is approved for acute myeloid leukemia (AML) in association with azacitidine, in a 28-day schedule at a fixed dosage, which requires reduction if azoles are co-administered. The present study aims to evaluate VEN therapeutic drug monitoring (TDM) in a real-word setting, where the VEN schedule is frequently reduced, investigating: (i) the posaconazole impact, and (ii) whether VEN exposure correlates with safety and efficacy. Methods: We analyzed data from 43 AML patients treated with different VEN-containing regimens, for whom a near-trough VEN plasma concentration (Cmin) was determined at different timepoints (days 5-8-11-15-22-29) across different cycles… More >